Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer
Anna E. Harris(University of Nottingham), Jennie Jeyapalan(University of Nottingham), Rupert G. Fray(University of Nottingham), Laura Martín(Imperial College Healthcare NHS Trust), Jenny L. Persson(Malmö University), Atara Ntekim(University College Hospital, Ibadan), Michael S. Toss(Nottingham City Hospital), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Chantelle Endeley(University of Nottingham), Emad A. Rakha(Nottingham University Hospitals NHS Trust), Maria Haque(University of Nottingham), Catrin S. Rutland(University of Nottingham), Victoria James(University of Nottingham), Simone de Brot(University of Bern), Juliette Brownlie(University of Nottingham), Veronika M. Metzler(University of Nottingham), Lorraine J. Gudas(Cornell University), Francesca Khani(Cornell University), Jennifer Lothion‐Roy(University of Nottingham), Daisy B. Haigh(University of Nottingham), Mansour Alsaleem(University of Nottingham), Cinzia Allegrucci(University of Nottingham), Dhruvika Varun(University of Nottingham), Nigel P. Mongan(University of Nottingham), Corinne L. Woodcock(University of Nottingham), Brian D. Robinson(Cornell University), Jenna E. Moyer(Cornell University)
Cited by 46
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Mutations of the TGF-β type II receptorBMPR2 in pulmonary arterial hypertension
|Human Mutation|2006|404